MedTrace Logo

Ibd CAncer and seRious Infections in France (I-CARE 2)

NCT06089590 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 6000

Last updated 2025-03-14

No results posted yet for this study

Summary

This is a French prospective longitudinal observational multicentre cohort study.

Primary objective : to assess prospectively the presence and the extent of safety concerns (cancer, serious infections, arterial and venous thrombotic events) in patients with CD and UC and treated with JAKi, anti-IL23p19, and S1p modulators.

Conditions

Interventions

OTHER

Non-interventional

This study is non-interventional, patients will be enrolled when initiating a treatment through standard of care procedures.

Sponsors & Collaborators

  • Sanoia

    collaborator OTHER

  • Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives

    lead OTHER

Principal Investigators

  • Julien Kirchgesner · Hôpital Saint Antoine - APHP

  • Mathurin Fumery · CHU Amiens-Picardie

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-25
Primary Completion
2031-03-01
Completion
2031-03-01

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06089590 on ClinicalTrials.gov